The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

CeriBell, Inc. (NASDAQ:CBLL) is among the Best Brain-Computer Interface Stocks.

On June 8, CeriBell, Inc. (NASDAQ:CBLL) reported a study published in Critical Care Medicine that higher AI-detected seizure burden is linked with increased odds of disability results at discharge. It analyzed 359 adult patients across three academic centers.

The company said patients with a peak seizure burden of at least 90% were 3.4 times more likely to experience death or severe disability compared to those with no seizure burden. Hence, the elevated burden directly leads to poorer functional outcomes.

The medtech firm revealed that risk develops with time. It stated that each additional hour of AI-detected seizure activity nearly doubled the odds of severe disability or death, noting an adjusted odds ratio of 1.98.

Lead author Josef Parvizi said the algorithm detects clinically relevant biomarkers with prognosis, underlining potential for earlier intervention.

CEO Jane Chao said continuous monitoring allows live assessment and more informed clinical decisions.

CeriBell, Inc. (NASDAQ:CBLL) is a commercial-stage medical technology firm that works to transform the diagnosis and treatment of patients with severe neurological conditions.

While we acknowledge the potential of CBLL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.